ERBB2 and breast cancer: While the current study reports a favorable survival outcome for the entire breast cancer cohort (3‐year overall survival of 41%), there are significant differences in survival outcomes based on receptor status (3‐year overall survival of 47% for LA, 39.2% for LB, 28.1% for HER2, and 8.3% for TN).